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The mechanistic requirements of antigen recognition by T cells expressing a γδ TCR has
revealed important differences with those of αβ TCR cells and, despite impressive new
data generated in the very recent years, they remain poorly understood. Based on the
structure of theTCR chains and the tissue distribution, γδ cells are represented in a variety
of populations. The major subset of human peripheral blood γδ cells express Vγ9Vδ2 TCR
heterodimers and are all stimulated by phosphorylated metabolites (commonly called phos-
phoantigens). Phosphoantigens are molecules with a very small mass and only stimulate
Vγ9Vδ2 cells in the presence of antigen-presenting cells, suggesting a strict requirement for
dedicated antigen-presenting molecules. Recent studies have identified butyrophilin (BTN)
3A1 as the molecule necessary to stimulateVγ9Vδ2 cells. BTN3A1 extracellular, transmem-
brane, and cytoplasmic domains have different functions, including cognate interaction with
theVγ9Vδ2TCR, binding of the phosphoantigens, and interaction with cytoplasmic proteins.
This review mainly discusses the known molecular mechanisms of BTN3A1-mediated anti-
gen presentation to γδ cells and proposes a model of phosphoantigen presentation, which
integrates past and recent studies.
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INTRODUCTION
Two types of TCR can be expressed in a mutually exclusive man-
ner by T cells made up of either αβ or γδ chains. Both receptors
are heterodimers, and while the TCR γ and β genes are encoded
in different loci, the TCR δ genes, being nested within the TCR α
locus, are subject to deletion when the TCR α genes are rearranged.
T cells expressing TCR homologous to the human TCR γ and
TCR δ genes have been described in many species, indicating an
important function of γδ TCR cells. Despite the enormous num-
ber of studies on γδ TCR cells, a series of issues remain poorly
solved. They include the evolutionary necessity for two separate
populations of T lymphocytes (1), the nature of the antigens that
stimulate γδ TCR cells, and the mechanisms of antigen presenta-
tion and the role of these cells in immune response. This paper will
only touch upon some of these points to review in greater detail
the published studies on the most abundant population of circu-
lating human γδ cells, their antigen specificities, and the modes of
presentation of these antigens.
THE STRUCTURE OF THE γδ TCR
Both αβ and γδ TCRs are heterodimers linked by disulfide bonds.
Some rare γδ TCR, namely those using the constant γ2 chain,
lack a critical cysteine and thus form non-covalently linked
heterodimers. Whether this structural difference has important
functional effects remains poorly investigated.
The structures of human γδ TCR have been solved and
showed pairing of the γ and δ chains, resembling that of αβ
TCR heterodimers (2). The complementarity-determining region
3 (CDR3) regions of both γ and δ genes form quite large bulges on
the top of the receptor, suggesting a direct involvement in antigen
recognition (3). A second main aspect is that the human TCR com-
posed of the Vγ9 and Vδ2 chains is characterized by an elbow angle
at the C–V junction, which is different from that of the αβ TCR of
immunoglobulins (2). It was speculated that other γδ TCR com-
posed of non-Vγ9 and non-Vδ2 chains also show similar angles,
as the residues found in the V–C interface of the solved Vγ9Vδ2
TCR are conserved in most human and mouse γ and δ genes (4).
Although this unique structure might have important functional
implications, no study has directly addressed this aspect.
The CDR loops of the TCR γ and TCR δ chains closely resem-
ble those of other TCR genes, though important differences are
present. The CDR1 and CDR2 loops of Vγ and the CDR1 loop
of Vδ are positioned in a manner similar to those of Vβ and Vα,
respectively, and they are two residues longer than their αβ TCR
counterparts. In addition, in the CDR2 loop of Vδ, the C′′ strand
pairs with the C′ strand of the innerβ-sheet of the domain, whereas
in the Vα chain CDR2 loop, the C′′ strand pairs with the D strand
of the outer β-sheet. These structural characteristics contribute to
a jagged surface of the γδ TCR, which is very different from that of
a αβ TCR that binds MHC–peptide complexes, implying that the
surface of the antigen-presenting molecule interacting with the
Vγ9Vδ2 TCR is very different from that of an MHC molecule.
Other studies have investigated the structure of different types
of γδ TCR and their mode of interaction with respective ligands.
The Vδ1 chain of an MICA-reactive T cell showed a surprisingly
flat surface, which is not found in other TCR structures (3), impli-
cating an interaction very different from that of αβTCR with MHC
molecules.
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A TCR recognizing the MHC class I-like molecule T22 showed
dominance in this interaction of the germline-encoded residues of
the junctionally recombined CDR3δ, which bound to the α helices
of T22 (5), a mode of antigen recognition different from that of
antibodies and MHC-restricted TCR.
THE ANTIGENS STIMULATING γδ CELLS
The conservation of the γ and δ genes throughout the primate
lineage suggests that these distinctions probably have important
functional consequences.
Since the initial discovery of the T cell population express-
ing the γδ TCR, it was clear that the identification of the nature
of stimulatory antigens was an important step to understanding
the function of γδ TCR during immune responses. A variety of
antigens have been identified and their nature has been recently
reviewed in Ref. (6). Here, we briefly describe the published stud-
ies reporting antigens, which stimulate TCR γδ cells and discuss
them according to their nature and expression on target cells.
SURFACE MOLECULES STIMULATING γδ TCR CELLS
The list of cell surface molecules that may establish cognate inter-
actions with the γδ TCR is large and is continuously increasing
(Table 1). All of the identified surface molecules stimulate a small
Table 1 | Antigens stimulating γδ cells.
γδTCR/cell type Antigens/restriction molecules Reference
HUMAN
Vγ (several) Vδ1 MICA, MICB (3, 22)
Vγ (several) Vδ1 CD1c, CD1d (12–17)
Vγ4Vδ5 EPCR (18)
Vγ9Vδ2 F1 ATPase, Apo A-I (23)
Vγ9Vδ2 GroEL homolog on Daudi
Burkitt’s lymphoma cells
(25)
Vγ9Vδ2 Hsp60, Hsp65 (24, 26, 27)
Vγ9Vδ2 IPP, HMBPP (43–45)
Tetanus toxoid (30, 31)
DXS2 or Rv2272 peptides (40)
Vδ1 clones HLA-A24, HLA-A2 (9, 10)
Vγ4Vδ1 HLA-B27 (32)
Vγ3Vδ2 Histidyl-tRNA synthetase (39)
MOUSE
Hybridoma G8 T10, T22, T27 (5, 11, 21)
Hybridoma KN6 T27 (11, 19)
Hybridoma LBK5 IEk (11)
Vγ1Vδ8 (NX6) Cy3 (41)
Vγ4Vδ4 (1G9) NP (41)
Vγ1–Jγ4/Vδ5 (MA2) PE (42)
Apo A-I, apolipoprotein A-I; CD1c or CD1d, cluster of differentiation 1 isoforms;
Cy3, cyanine 3; DXS2, mycobacterium 1-deoxy-D-xylulose-5-phosphate-synthase
2; EPCR, endothelial protein C receptor; HLA, human leukocyte antigen; HMBPP,
(E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate; Hsp, heat-shock protein; IPP,
isopentenyl pyrophosphate; MICA or MICB, MHC class I chain-related protein A
or B; NP, 4-hydroxy-3-nitrophenylacetyl; Rv2272, mycobacterium transmembrane
protein; T10, T22, or T27, MHC class Ib proteins; PE, algae protein phycoerythrin.
percentage of γδ cells and raise the important question of whether
these specificities are occasional or instead should be considered
as an important part of the antigenic repertoire of γδ cells. MHC
molecules were found to stimulate alloreactive responses of γδ
cells (7–10), and mutagenesis studies on the MHC molecule indi-
cated that the topology of γδ TCR interaction with the MHC was
distinct from that of αβ T cells (11).
CD1 molecules have been found to interact with the human γδ
TCR. The first isolated human T cell clone showed CD1c autoreac-
tivity (12) and other CD1c-autoreactive γδ TCR cells were found
later (13, 14). Rare CD1d-restricted γδTCR cells were identified by
staining with CD1d tetramers loaded with α-Galactosylceramide
(15) or with sulfatide (16, 17). Vδ1 was the Vδ chain used in both
types of γδ cells and it was the predominant chain interacting with
CD1d. The Vγ chain was found contacting α-Galactosylceramide
(15), whereas in the case of sulfatide recognition, the Vγ chain
interacted neither with CD1d nor with sulfatide (17).
Another surface molecule with a CD1d-resembling structure,
which stimulates a rare population of γδ cells is the endothelial
protein C receptor (EPCR) (18), a lipid-binding protein expressed
by endothelial cells. One T cell clone expressing a Vδ5–Vγ4 TCR
interacted with low affinity with EPCR, and this interaction was
facilitated by CMV infection. The enhancing effect of CMV was
not related to changes in EPCR lipid binding and remains poorly
characterized.
Other MHC-like molecules interacting with mouse γδ cells are
TL 27b (19), TL 10b (11, 20), and T22 (21). The structure of the
specific TCR bound to the T22 molecule showed that germline-
encoded residues of the CDR3δ loop were responsible for binding
T22 in an orientation different from that seen in αβ TCR bind-
ing to MHC–peptide complexes (5). Human Vδ1-expressing cells
were also found to interact with the MICA molecule (22). The Vδ1
TCR of these cells and the NKG2D, another MICA receptor, bound
MICA in a mutually exclusive manner. The analysis of the binding
kinetics suggested a model in which the initial contact between the
γδ cells and the target cell is established by fast binding of MICA to
NKG2D, followed by a much-prolonged interaction with the TCR.
Two other proteins were reported to stimulate human Vγ9Vδ2
cells, namely “an entity related to the mitochondrial F1 ATPase”
expressed by some tumor cells and a delipidated form of
apolipoprotein A-I (Apo A-I) (23). A soluble Vγ9Vδ2 TCR was
found to interact with Apo A-I and bovine F1 ATPase in the low
micromolar range by surface resonance (SPR) studies. When dif-
ferent Vγ9Vδ2 clones were compared, only some were positively
influenced by the presence of Apo A-I, indicating a redundant role
of this molecule.
A last set of proteins that were reported to stimulate human γδ
cells are heat-shock proteins (24–26). Surface expression of these
molecules was associated with targeting of γδ cells on different
tumor cells (27).
All these findings suggest that antigen recognition by γδ T cells
is different from that of αβ T cells. The different length of both Vγ
and Vδ CDR3 loops also supports this conclusion. These loops are
often critical for antigen binding in Ig and significantly contribute
to peptide binding in αβ TCRs. When the CDR3 regions of Ig H
and L chains are compared with those of TCR α, β, γ, and δ chains,
the one from Ig H and TCR δ are the most variable in size and
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are significantly longer than Ig L and TCR γ chains, respectively
(28). In contrast, TCR α and β pairing occurs with chains of nearly
identical average CDR3 lengths. These important TCR structural
differences have been related to a type of antigen recognition by
γδ TCR similar to that of Ig (29).
SMALL MOLECULES STIMULATING γδ TCR CELLS
Several studies have identified both human and mouse γδ T cells
that were activated by small peptides, carbohydrates, and hap-
tens. Initial studies showed the existence of human and mouse
γδ cells recognizing MHC–peptide complexes expressed on the
surface of antigen-presenting cells (APC) (10, 30–32). In contrast
with human alloreactive αβ TCR cells, the number of alloreac-
tive γδ cells remains quite rare. H2-peptide-specific γδ TCR cells
were found in mice, after inhalation of ovalbumin (33). Whether
these γδ cells recognize intact ovalbumin or its peptides was not
investigated.
Mouse γδ TCR hybridomas recognizing peptides from heat-
shock proteins were also described. Interestingly, these peptides
were presented by non-MHC molecules and their recognition was
sensitive to amino-acid changes in the peptide sequences and to the
type of Vγ chain expressed by specific hybridomas (34). Another
study described mouse γδ cells recognizing glycosylated peptides
in which MHC class I-bound peptides with two or three sugars
were stimulatory (35). The central position of the sugar in the pep-
tide sequence was critical for stimulation (36), probably because
of direct interaction with the γδ TCR.
Several studies have shown that in some patients with
myopathies, γδ cells infiltrate the affected area and are associated
with acute pathology (37). In one study, the infiltrating T cells were
cloned and found to be oligoclonal (38). The TCR of these cells was
composed of a Vγ1.3–Jγ1–Cγ1/Vδ2–Jδ3 heterodimer, which is not
frequent in normal donors. This TCR recognized histidyl-tRNA
synthetase, an antigen also recognized by anti-Jo-1 autoantibodies
(39). The γδ TCR target epitope was strictly conformational, inde-
pendent of post-translational modification, exposed on the surface
of the intact protein, and mutagenesis studies showed that a short
alpha-helical loop constituted part of the γδ stimulating epitope.
Recent studies reported the identification of two mycobacte-
rial proteins, namely 1-deoxy-d-xylulose 5-phosphate synthase
2 and Rv2272 protein, which activated γδ T cells isolated from
patients with pulmonary tuberculosis (40). Two peptides, 12
amino-acid long from each of these proteins, retained the capacity
of stimulating a major population of γδ cells expressing a unique
CDR3δ segment. Whether this recognition occurred by cognate
interaction of the TCR with the peptides or via a dedicated
presenting molecule was not investigated.
More recently, mouse γδ cells specific for small haptens have
been identified (41). These T cells recognized cyanine 3, a syn-
thetic fluorescent molecule, and 4-hydroxy-3-nitrophenylacetyl, a
classical hapten. Another small molecule stimulating both murine
and human γδ TCR cells is the algae protein phycoerythrin (PE)
(42). The TCR of isolated cells directly interacted with the whole
PE, thus indicating a B cell-like antigen recognition capability.
Another type of small antigens stimulating γδ cells is repre-
sented by phosphorylated metabolites generated in the meval-
onate pathway in eukaryotic cells or in the methyl erythritol
pathway in bacteria and in some eukaryotes. The most represen-
tative stimulatory molecules are isopentenyl pyrophosphate (IPP)
(43, 44) and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate
(HMBPP) (45) (Figure 1). Both are very small molecules with a
molecular weight of 245 and 262, respectively, and are composed of
one isoprene unit to which a diphoshate is attached. Small changes
in the structure of these ligands, either on the phosphate or the iso-
prene moieties, profoundly affect the γδ cell stimulatory capacity.
Several analogs of these compounds have been synthesized with
an intermediate stimulatory capacity between that of IPP and of
HMBPP [reviewed in Ref. (46)]. The same population of γδ cells
also recognizes some tumor cells. This recognition is ascribed to
the abnormally elevated production of IPP by tumor cells, as result
of changes in the regulation of their mevalonate metabolic path-
way (47). All of these findings show that γδ cells may cross-react
to phosphorylated metabolites accumulating inside tumor cells
and to metabolites released by bacterial cells in the microenviron-
ment. Importantly, when bacteria infect target cells, they induce
alteration of the host mevalonate pathway by subverting several
regulatory mechanisms (48). These alterations lead to a transient
and acute accumulation of IPP, which is then responsible for the
activation of γδ cells. In conclusion, γδ cells may recognize (i)
tumor cells that accumulate IPP; (ii) bacterial metabolites such as
HMBPP, and (iii) cells accumulating IPP following infection with
bacteria not producing HMBPP.
An important finding is that these metabolites stimulate the
human cells expressing the Vγ9Vδ2 heterodimer and also other
primate γδ cells, which express TCR heterodimers closely resem-
bling the Vγ9Vδ2 TCR (49). The role of the CDR3 sequences of
FIGURE 1 | Structure of the two most common phosphorylated metabolites stimulatingVγ9Vδ2 cells. The arrows indicate the parts of the molecules
whose modifications significantly reduced immunogenicity.
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Vγ9Vδ2 TCR in antigen recognition remains debated. Sequence
analysis of T cell clones reacting to IPP and HMBPP (50–54)
showed CDR3 regions of different length and sequences, thus indi-
cating that they are unlikely to be involved in direct contact with
such small antigens. In addition, most peripheral, but not thymic
Vγ9Vδ2, clones contained Val or Leu or Ile amino acids at posi-
tion 97 of the CDR3δ (55), raising the possibility of a selection
for hydrophobic residues during expansion in peripheral blood.
The conclusions of these investigations were in line with more
recent data in which the mutation of the TCR Vγ9 and Vδ2 genes
suggested that a large TCR footprint is involved in antigen stim-
ulation (56), probably because the TCR interacts with molecules
much larger than the small stimulatory metabolites.
Although the stimulation of γδ cells by phosphoantigens has
been described for many years, important cell biology aspects
of how the Vγ9Vδ2 TCR engages these molecules remained
poorly defined. Classical studies of antigen presentation were
performed in different laboratories and provided useful infor-
mation to the understanding of how this interaction may occur.
APC were necessary for this activation and only human APC
could activate Vγ9Vδ2 cells, suggesting that antigen-presenting
molecules or surface-expressed co-stimulatory molecules were
necessary (57). These observations were confirmed in other stud-
ies (58, 59). Cells from many different human tissues (47), from
different donors, and APC neither expressing MHC class II mole-
cules nor β2-microglobulin (57) were also stimulatory indicating
that the required presenting/accessory molecule is ubiquitous,
non-polymorphic, and species-specific.
Fixed APC maintained the capacity to stimulate Vγ9Vδ2 cells
as shown by lymphoma Daudi cells (25), which accumulate
endogenous IPP (47). Fixed APC remained stimulatory also when
exogenous IPP was added after fixation (60), indicating that
metabolically inactive APC remain stimulatory. This informa-
tion also suggested that the exogenous antigen does not require
specific internalization into APC and that the presenting mole-
cule is already expressed in a stimulatory form on Daudi cells
before fixation and so it remains after fixation. In one study, the
responsiveness of Vγ9Vδ2 cells to a crude mycobacterial lysate
was investigated (61). When monocytes were first pulsed and then
fixed, they retained the stimulatory capacity, whereas they were
not stimulatory if pulsed after fixation. This study also showed
that chloroquine increased the antigen-presenting capacity of APC
and this effect was not associated with inhibition of lysosome
acidification. It was suggested that chloroquine facilitates antigen
presentation by decreasing the degradation or turnover of surface
presenting molecules. These studies underlined the importance of
surface molecules that can be fixed in a stimulatory state upon
antigen binding.
Several laboratories also reported that phosphoantigens cannot
be pulsed on APC, i.e., when APC are incubated with phospho-
antigens, they immediately lose their stimulatory capacity upon
washing (58, 60), probably caused by a weak binding to, and a
fast dissociation from, the presenting molecule. This behavior is
incompatible with a cytoplasmic stimulatory activity of phospho-
antigens, and is instead in agreement with an extracellular role of
a presenting molecule on APC. Consistent with a weak extracellu-
lar antigen binding, association of prenyl pyrophosphate antigens
with the surface of APCs was reported only in the presence of 50-
to 1000-fold higher concentrations of antigen than those required
to stimulate γδ cells (62).
Another important finding was that the addition of the anti-
gen to APC is immediately followed by T cell response. This was
observed in several kinetic studies (58, 63, 64). Using cytosensor
microphysiometry, γδ T cell activation was detected in <9 s after
antigen addition (63). As charged compounds passively pass the
plasma membrane with great difficulty (65) and require an active
endocytic process, it is unlikely that phosphoantigens added to the
extracellular milieu may accumulate in the cytoplasm of APC in
<9 s. Such a fast T cell response is in agreement with the possibil-
ity that the antigen binds to surface molecules almost immediately
and that internalization into the APC is not necessary.
Other clues to the nature of antigen binding comes from stud-
ies of stimulatory and inhibitory capacity of IPP (66) and HMBPP
(63) analogs. Antagonistic activity was found with some ligands,
and in one case, γδ cells became unresponsive after a very brief
interaction (<5 min) with the antagonist compounds (66). This
state of unresponsiveness was fully reversible but lasted at least
3 days even after removal of the antagonist, thus indicating that
the interaction with the antagonist induced a significant change
in γδ cells. This observation is in agreement with a model of anti-
gen recognition in which antigenic molecules exposed on the cell
surface bind phosphorylated metabolites and, according to their
structure, an agonist or antagonist signal is induced in the interact-
ing γδ cells. It remains intriguing that when competition studies
were performed using methylene diphosphonates, higher doses of
competitors were required to inhibit stimulation with IPP than
with BrHPP (63) despite the fact that IPP is a weaker agonist than
BRHPP (67). Further investigations are required to explain this
unexpected result.
A significant finding was that the Vγ9Vδ2 TCR enters the
immune synapse in the absence of antigen (68), thus suggesting
that this TCR may interact with molecules already exposed on the
APC surface in the absence of phosphoantigens. This interaction
is enough to form an APC-T cell synapse, although it is not capa-
ble of inducing a full γδ cell response, which instead requires the
presence of the antigen.
THE ROLE OF BUTYROPHILINS IN STIMULATING γδ CELLS
An important advancement was made by the identification of
Butyrophilin (BTN) 3A1 (BTN3A1) as the molecule required to
stimulate Vγ9Vδ2 cells by phosphoantigens (69, 70). This mol-
ecule belongs to the family of BTN (Figure 2), which have been
attributed a series of functions including immunomodulation (71,
72) and induction of maturation of mouse thymic Vγ5Vδ1 cells
(73). BTN proteins can be involved in milk fat globule formation
in the lactating mammary tissue of cows (74), or in dampening
and inhibiting immune reactivity (71, 72).
The BTN3 family is conserved together with the TCR Vγ9 and
Vδ2 genes in higher primates and in some species of placental
mammals, but not in rodents (75). The common occurrence or
loss of these three genes suggested their co-evolution based on a
functional relationship.
Butyrophilins are structurally very similar to molecules of
the B7 family. A major characteristic shared among the B7,
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FIGURE 2 | Cladogram and schematic diagram of human BTN and BTNL
family members. Protein sequences were aligned with ClustalW2 and the
tree rendered using FigTree software (tree.bio.ed.ac.uk/software/figtree).
Diagram shows the domain organization of members belonging to the BTN
family consisting of two extracellular Ig-like domains, IgV and IgC, a
single-pass transmembrane domain (TM) and an intracellular B30.2 domain.
Exceptions include BTN1A1, consisting of a short IgV-like domain; BTN3A2,
lacking a B30.2 domain; BTNL9, containing a single Ig-like domain; and
BTNL2, consisting of four extracellular Ig-like domains and lacking a B30.2
domain.
BTN, and butyrophilin-like (BTNL) families is the two extra-
cellular immunoglobulin-like domains – one IgV-like and one
IgC-like domain. Some members, like BTNL2 and B7 homolog
3 (B7H3), instead comprise four extracellular immunoglobulin-
like domains. Like several members of the B7 family (76), BTN
proteins have also been found to form dimers (77), although
their occurrence on the surface of APC remains to be confirmed.
Structural studies with soluble BTN3 molecules have shown the
formation in solution of two types of BTN3 dimers (77). One type
is formed by juxtaposition of the C-like domains (head-to-head
dimer), resembling the dimers formed by B7 family members.
In contrast, the second type of dimer was characterized by an
asymmetric head-to-tail binding. Fluorescence resonance energy
transfer experiments suggested that the head-to-head dimers are
more frequently formed, at least in solution.
Importantly, when reconstitution experiments were performed
by transfecting the BTN3A1 gene in mouse cells, it was found that
this protein alone is not sufficient to restore the stimulation of
Vγ9Vδ2 cells (69, 70, 78), suggesting that additional molecules are
necessary.
A common feature of the BTN and BTNL families (with the
exception of BTN3A2 and BTNL2) is the presence of intracellular
domains with a structure resembling the B30.2 domain found in
more than 150 other human proteins (79). This domain forms
protein–protein interactions with various cytoplasmic molecules
with different activities (80).
One study describing the stimulatory role of an anti-BTN3A1
monoclonal antibody (mAb) (69) provided early insights into the
mechanism of BTN3A1–phosphoantigen presentation. When this
antibody was added to target cells expressing BTN3A1, it induced
the activation of Vγ9Vδ2 cells independently of the presence
of phosphoantigens. A second anti-BTN3A1 mAb was instead
inhibitory. These findings raised a series of new questions asso-
ciated with the occurrence of both stimulatory and inhibitory
anti-BTN mAbs. This issue was further studied by resolving the
structure of BTN3A in association with the two mAbs (77). Indeed,
while the inhibitory antibody bound to the distal part of the V-like
domain, the stimulatory antibody bound to a more membrane
proximal region of the V-like domain. The activatory antibody
was also found to be compatible with in vitro formation of BTN3
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homodimers in which the C-like domains of two BTN3 molecules
interact with each other, as reported for other B7-like mole-
cules. The authors speculated that the capacity of this antibody
to facilitate this type of dimers was associated with the stimula-
tory capacity of this mAb, whereas the inhibitory mAb prevented
BTN3 homodimerization.
A second study used a genetic approach to identify the chromo-
somal loci encoding the gene required for stimulation of Vγ9Vδ2
cells (70). By using a panel of mouse–human somatic cell hybrids,
the telomeric region of human chromosome 6 was identified
as important. By using a second series of somatic hybrids with
truncations in this region, a closer genetic mapping identified 14
candidate genes, and among those BTN3A1 was found necessary
for stimulating γδ cells. Transfection and knock out studies con-
firmed that while BTN3A1 was important, BTN3A2 and BTN3A3
had no apparent role in stimulating Vγ9Vδ2 cells. Additional
experiments investigated the mechanism of BTN3A1 stimula-
tion. A recombinant BTN3A1 protein containing only the V-like
domain showed binding to IPP and HMBPP. This was investigated
using three different approaches, namely SPR, mass spectrome-
try of intact BTN3A1–antigen complex, and structural analysis
of BTN3A1–IPP and HMBPP complexes. These studies showed a
weak interaction of the two phosphoantigens with BTN3A1 and
indicated their mode of binding. Additional studies addressed the
important issue of whether the Vγ9Vδ2 TCR makes cognate inter-
action with the BTN3A1–phosphoantigen complexes. This aspect
was initially investigated by SPR and then by surface-enhanced
Raman scattering (SERS), a technique capable of detecting very
weak protein–protein interactions. These studies revealed that
only a soluble Vγ9Vδ2 TCR interacted with the complex, and
neither soluble Vγ9Vδ1 TCR nor αβ TCR used as controls. The
Vγ9Vδ2 TCR weakly interacted with the recombinant BTN3A1 in
the absence of phosphoantigens and this interaction was enhanced
by addition of IPP (70).
Another important finding was that when the cytoplasmic
B30.2 domain of BTN3A1 was grafted on the non-stimulatory
BTN3A3 molecule, stimulation of Vγ9Vδ2 was restored (69).
Thus, both the extracellular and the cytoplasmic domains of
BTN3A1 were required (Figure 3). The importance of intracel-
lular domains has been already reported in the field of antigen
presentation. Indeed, the cytoplasmic domains of other antigen-
presenting molecules, for example, CD1 molecules, are involved in
proper internalization, endosomal recycling, and in the physiolog-
ical presentation of lipid antigens (81). The cytoplasmic domains
of several presenting molecules associate with different protein
partners and each of these interactions contribute to antigen
presentation and productive T cell activation.
In more recent studies, binding of IPP and HMBPP to the B30.2
domain and not to the V-like domain of BTN3A1 was reported
(82, 83), and mutagenesis studies of the B30.2 domain of the non-
stimulatory BTN3A3 where an amino-acid change in the putative
antigen binding pocket to that of BTN3A1 conferred binding of
HMBPP and γδ cell stimulatory capacity (82). In this latter study,
no binding of the TCR to the V-like domain of BTN3A1 was
detected and it was proposed that the B30.2 domain is important
because it binds phosphoantigens and with unknown mecha-
nisms it induces the activation of γδ cells. Although interesting,
FIGURE 3 | Diagram of BTN3A1 topology. The extracellular Ig-like
domains (green) and the intracellular B30.2 domains (orange) are illustrated
here with available crystal structures (PDB IDs: 4F80 and 4N7U). The
relative orientation of the domains is arbitrary as depicted by the dotted
ovals. Site 1 and Site 2 represent the two identified binding sites of
phosphoantigens.
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this hypothesis is inconsistent with the published literature dis-
cussed above. The incapacity of detecting phosphoantigen and
TCR binding to the V-like domain of BTN3A1 might be ascribed
to technical reasons, for example, utilization of techniques not
capable of detecting weak protein–protein interactions and lack
of adequate control of the proper conformation of recombinant
molecules studied.
As described above, a large number of data obtained in sev-
eral laboratories indicated that phosphoantigens must be present
outside the APC to stimulate γδ cells and these data are not com-
patible with a model in which exogenous phosphoantigens must
first be internalized into the cytoplasm to become active. The fact
that the B30.2 domain of BTN3A1 binds the phosphoantigens
in vitro is not proof that similar binding occurs in vivo. This is
a main issue that has not been experimentally tested, but is fun-
damental to proposing the hypothesis of the intracellular mode
of phosphoantigen activity. As there is common agreement that
the B30.2 domain has a major role in activation of Vγ9Vδ2 cells,
other possibilities should be considered to explain its mode of
function. One hypothesis is that the B30.2 domain binds to one
or several cytoplasmic proteins instrumental for the correct dis-
play of BTN3A1. A second possibility is that the B30.2 domain is
necessary for the correct recycling of BTN3A1 to endosomal com-
partments. According to this latter possibility, the B30.2 domain
would resemble the cytoplasmic tails of other antigen-presenting
molecules that bind to cytoplasmic signaling partners and direct
BTN3A1 trafficking to compartments where the antigen is loaded
and unloaded. These alternative mechanisms of action require
the presence of unique motifs in the B30.2 domain. It is possible
that some of these important motifs could have been lost in the
mutagenesis study (82).
On the basis of all these data, we propose a model of activation
of Vγ9Vδ2 cells by phosphoantigens whereby the Vγ9Vδ2 TCR
makes cognate interaction with the BTN3A1 molecule (Figure 4).
The interaction of the TCR with the V-like domain of BTN3A1 is
positively influenced by the presence of phosphoantigens through
two possible mechanisms. The first one takes into account that
the phosphoantigens interact with the TCR, thus increasing the
overall affinity of interaction as suggested by SERS experiments
(70). Alternatively, phosphoantigen binding may induce a con-
formation change in BTN3A1, which in turn interacts with the
TCR, leading to a full activation of γδ cells. Both these possibili-
ties are in line with the inhibitory function of antagonist analogs
(63, 66). The presence of an extracellular V-like domain is not
sufficient to activate Vγ9Vδ2 cells, as shown by the relevance of
the B30.2 cytoplasmic domain (69). This domain could also bind
phosphoantigens (82), and it remains difficult to envisage how γδ
cell activation is induced upon this interaction. One hypothesis
is that upon phosphoantigen binding to the B30.2 domain, the
extracellular domains of BTN3A1 assume a new conformation,
which promotes stable contact with the γδ TCR. Alternatively,
phosphoantigen binding to the B30.2 domain could facilitate
proper trafficking and membrane localization of BTN3A1. It is
important to underline that binding to the V-like and B30.2
domains may not be necessarily mutually exclusive. Phosphoanti-
gen binding to both domains may be needed for appropriate γδ
cell stimulation. A new series of mutagenesis and reconstitution
FIGURE 4 | Model of phosphoantigen presentation according to
published data and mechanisms of phosphoantigen handling by APC.
(1) Bacteria release HMBPP in the microenvironment or are internalized in
phagosomes where HMBPP may be stored. (2) HMBPP passes
phagosomal membranes and reaches BTN3A1 with unclear mechanisms.
(3) Cytoplasmic IPP accumulated in the cytoplasm passes the membrane of
endosomal compartments. (4) IPP may also pass the plasma membrane. (5)
BTN3A1 traffics from plasma membrane to endosomal compartments
where it encounters IPP. (6) IPP may also interact with the B30.2
cytoplasmic domain of BTN3A1. (7) Dimers of BTN3A1 containing IPP are
formed and traffic to the plasma membrane. (8) The TCR Vγ9Vδ2 interacts
with the BTN3A1 dimers and IPP facilitates this interaction.
experiments in BTN3-deficient APC are required to properly
address this issue.
An important aspect is how endogenous ligands, such as IPP
that is synthesized in the cytosol, are loaded onto the extracel-
lular V-like domain of BTN3A1. Such an event implies that IPP
crosses an endosomal membrane or the plasma membrane. Data
in our laboratory indicate that a dedicated transporter is required
for presentation of endogenous IPP. Remarkably, the transporter
is required only when IPP accumulates within the APC and not
when it is provided exogenously.
Although great advancement has been achieved in understand-
ing the mechanisms of Vγ9Vδ2 cell activation and phosphoantigen
presentation, many questions remain. For example, how is the
surface expression of BTN molecules regulated, in which cellular
compartment do they traffic, do they associate with other mol-
ecules intracellularly and/or on the plasma membrane, and how
do phosphoantigen antagonists inhibit BTN3A1? As members of
the BTN3 family have been found to interact with other surface
proteins, which are not γδ TCR and are not broadly expressed
(84), it will be also important to identify these other partners and
investigate their role in T cell responses.
The light shed by BTN3A1 on the conundrum of antigen pre-
sentation to Vγ9Vδ2 cells has exposed only the tip of an iceberg.
It will be very interesting to follow the evolution of this field
and the implications of BTN in stimulating other types of γδ
cells.
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